Current Report Filing (8-k)
22 Junho 2023 - 6:15PM
Edgar (US Regulatory)
0001571934
false
0001571934
2023-06-16
2023-06-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 16, 2023
Synaptogenix, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
001-40458 |
46-1585656 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
1185
Avenue of the Americas, 3rd
Floor
New York, New
York 10036
(Address of principal executive offices and zip code)
Registrant’s telephone number, including
area code: (973) 242-0005
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which
registered |
| Common Stock, $0.0001 par value per share |
|
SNPX |
|
The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company. x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02. |
Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As previously disclosed, on December
7, 2020, Synaptogenix, Inc. (the “Company”) entered into an offer letter with Alan J. Tuchman, M.D., pursuant to which Dr.
Tuchman agreed to serve as the Company’s Chief Executive Officer, and such letter was amended on August 4, 2022 to extend the term
of Dr. Tuchman’s employment through June 7, 2023 (as amended, the “Offer Letter”). On June 16, 2023, the Company entered
into a second amendment to the Offer Letter (the “Second Amendment”) to extend the term of Dr. Tuchman’s employment
through June 7, 2024, with automatic monthly renewals thereafter unless earlier terminated in accordance with the terms of the Second
Amendment.
The foregoing description of the
Second Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment,
a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| Date: June 22, 2023 |
By: |
/s/ Robert Weinstein |
| |
Name: |
Robert Weinstein |
| |
Title: |
Chief Financial Officer |
Synaptogenix (NASDAQ:SNPX)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Synaptogenix (NASDAQ:SNPX)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
